| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and nine months ended August 31, 2024 and 2023:
|
|
|
|
|
|
|
|
|
|
|
For the three months ended August 31, |
|
|
|
2024 |
|
|
2023 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
7,945,470 |
|
|
$ |
7,862,949 |
|
PrepaCyte CB |
|
|
636 |
|
|
|
2,543 |
|
Public cord blood banking |
|
|
120,609 |
|
|
|
4,383 |
|
Total net revenue |
|
$ |
8,066,715 |
|
|
$ |
7,869,875 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,859,090 |
|
|
$ |
1,976,278 |
|
PrepaCyte CB |
|
|
1,220 |
|
|
|
982 |
|
Public cord blood banking |
|
|
265,536 |
|
|
|
178,927 |
|
Total cost of sales |
|
$ |
2,125,846 |
|
|
$ |
2,156,187 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,542,346 |
|
|
$ |
1,341,332 |
|
PrepaCyte CB |
|
|
(7,529 |
) |
|
|
(5,384 |
) |
Public cord blood banking |
|
|
(144,927 |
) |
|
|
(174,904 |
) |
Total operating profit |
|
$ |
1,389,890 |
|
|
$ |
1,161,044 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
187,614 |
|
|
$ |
273,972 |
|
PrepaCyte CB |
|
|
6,945 |
|
|
|
6,945 |
|
Public cord blood banking |
|
|
— |
|
|
|
360 |
|
Total depreciation and amortization |
|
$ |
194,559 |
|
|
$ |
281,277 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
533,464 |
|
|
$ |
469,642 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
533,464 |
|
|
$ |
469,642 |
|
|
|
|
|
|
|
|
|
|
For the nine months ended August 31, |
|
|
|
2024 |
|
|
2023 |
|
Net revenue: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
23,716,492 |
|
|
$ |
23,006,164 |
|
PrepaCyte CB |
|
|
39,470 |
|
|
|
61,920 |
|
Public cord blood banking |
|
|
205,799 |
|
|
|
398,896 |
|
Total net revenue |
|
$ |
23,961,761 |
|
|
$ |
23,466,980 |
|
Cost of sales: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
5,574,109 |
|
|
$ |
5,466,410 |
|
PrepaCyte CB |
|
|
37,083 |
|
|
|
27,432 |
|
Public cord blood banking |
|
|
699,872 |
|
|
|
872,895 |
|
Total cost of sales |
|
$ |
6,311,064 |
|
|
$ |
6,366,737 |
|
Operating profit: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
4,115,571 |
|
|
$ |
4,333,538 |
|
PrepaCyte CB |
|
|
(18,447 |
) |
|
|
13,654 |
|
Public cord blood banking |
|
|
(494,493 |
) |
|
|
(475,079 |
) |
Total operating profit |
|
$ |
3,602,631 |
|
|
$ |
3,872,113 |
|
Depreciation and amortization: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
266,289 |
|
|
$ |
821,287 |
|
PrepaCyte CB |
|
|
20,834 |
|
|
|
20,834 |
|
Public cord blood banking |
|
|
420 |
|
|
|
1,080 |
|
Total depreciation and amortization |
|
$ |
287,543 |
|
|
$ |
843,201 |
|
Interest expense: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service |
|
$ |
1,119,196 |
|
|
$ |
1,405,825 |
|
PrepaCyte CB |
|
|
— |
|
|
|
— |
|
Public cord blood banking |
|
|
— |
|
|
|
— |
|
Total interest expense |
|
$ |
1,119,196 |
|
|
$ |
1,405,825 |
|
The following table shows the assets by segment as of August 31, 2024 and November 30, 2023:
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of |
|
|
|
August 31, 2024 |
|
|
November 30, 2023 |
|
Assets: |
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell
service |
|
$ |
57,318,175 |
|
|
$ |
55,471,149 |
|
PrepaCyte CB |
|
|
149,112 |
|
|
|
148,040 |
|
Public cord blood banking |
|
|
5,467,186 |
|
|
|
5,601,581 |
|
Total assets |
|
$ |
62,934,473 |
|
|
$ |
61,220,770 |
|
|